ENDRA Life Sciences amends merger deal with ASP Isotopes, raises Renergen loan capacity
ENDRA Life Sciences amended its June 25, 2026 merger agreement with ASP Isotopes and related parties on October 1, 2026, removing the classified board requirement, revising the minimum cash closing condition to $3,800,002.59 less agreed expenses, and allowing ASP-related lending to Renergen to rise from $80 million to up to $200 million. The company also amended warrants held by an ASP Isotopes affiliate to remove the 4.99% beneficial ownership limit, which changes how that affiliate can exercise them.
Key points
- Amendment dated October 1, 2026 changes the merger terms, including the minimum cash closing condition of $3,800,002.59, less agreed expenses.
- Renergen's ASPI borrowing capacity would rise from $80 million to up to $120 million, then to up to $200 million at or before closing.
- Warrant amendments remove the 4.99% beneficial ownership limitation for LHE LNG Holdings, an ASP Isotopes subsidiary.
- Warrants covering 324,372 pre-funded shares and all common warrants become exercisable only after stockholder approval.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.